复方苦参注射液联合伊班膦酸钠治疗多发性骨髓瘤骨痛的疗效观察

Efficacy of Compound Kushen Injection Combined with Sodium Ibandronate in the Treatment of Multiple Myeloma Bone Pain

目的:探讨复方苦参注射液联合伊班膦酸钠治疗多发性骨髓瘤骨痛的临床疗效。方法:选取2018年10月至2020年10月华北理工大学附属医院收治的初治多发性骨髓瘤患者80例,通过随机数字表法分为治疗组40例和对照组40例。所有患者均给予硼替佐米、来那度胺及地塞米松方案治疗。在此基础上,对照组患者给予伊班膦酸钠治疗,治疗组患者给予复方苦参注射液联合伊班膦酸钠治疗。比较两组患者的近期疗效、疼痛评分、卡诺夫斯凯计分(KPS)、血清碱性磷酸酶(ALP)水平及不良反应发生情况。结果:治疗组患者的治疗总缓解率为95.0%(38/40),明显高于对照组的80.0%(32/40),差异有统计学意义(P<0.05)。治疗后,两组患者的KPS评分明显改善,疼痛评分、ALP水平明显降低,且治疗组患者的KPS评分、疼痛评分和ALP水平优于对照组,差异均有统计学意义(P<0.05)。治疗组患者的不良反应发生率为25.0%(10/40),略低于对照组的37.5%(15/40),但差异无统计学意义(P>0.05)。结论:复方苦参注射液联合伊班膦酸钠可治疗多发性骨髓瘤,能有效缓解患者骨痛,提高疗效和生活质量。

OBJECTIVE:To probe into the clinical efficacy of compound Kushen injection combined with sodium ibandronate in the treatment of multiple myeloma bone pain.METHODS:Totally 80 patients newly diagnosed with multiple myeloma admitted into the Affiliated Hospital of North China University of Science and Technology from Oct.2018 to Oct.2020 were selected and divided into treatment group(40 cases)and control group(40 cases)via random number table.All the patients were treated with bortezomib combined with lenalidomide and dexamethasone.On that basis,the control group was given sodium ibandronate,while the treatment group was given compound Kushen injection combined with sodium ibandronate.The short-term efficacy,pain score,KPS score,serum serum alkaline phosphatase(ALP)level and incidences of adverse drug reactions were compared between two groups.RESULTS:The total remission rate of treatment group was 95.0%(38/40),significantly higher than that of the control group(80.0%,32/40),with statistically significant difference(P<0.05).After treatment,the KPS scores were significantly improved,the pain scores and ALP levels were significantly decreased both groups,while the KPS score,pain score and ALP level were better in the treatment group than in the control group,with statistically significant differences(P<0.05).The incidences of adverse drug reactions of the treatment group was 25.0%(10/40),lower than 37.5%(15/40)of the control group,the difference was not statistically significant(P>0.05).CONCLUSIONS:Compound Kushen injection combined with sodium ibandronate can treat multiple myeloma,which can effectively relieve patients’bone pain,improve clinical efficacy and life quality.